ALK+ aNSCLC: Nordic perspectives on treatment selection and management for long-term care

ALK+ aNSCLC: Nordic perspectives on treatment selection and management for long-term care | Webinar | Pfizer

This webinar will provide an updated overview of ALK inhibitor therapy in advanced NSCLC, including discussion of long-term (7-year) follow-up data for lorlatinib. The program focuses on pragmatic, day-to-day clinical practice, covering treatment selection and practical management of ALK inhibitor therapy, informed by real-world clinical experience. The webinar is aimed at lung cancer–treating physicians across the Nordic countries and the Netherlands.

Live webinar, free of charge. The speaker’s fee will be covered by Pfizer.

_{PP-UNP-SWE-1193 May 2026}